Cancer has been treated by hormonal manipulation for over 100 years. Although therapeutic progress during this period has resulted mainly from clinical observation, more rational treatment approaches are now emerging from insights into the molecular basis of hormone-responsiveness. Among these are the recognition that hormonal signalling effects are transduced via specific receptor proteins, and the possibility that tumour lysis by hormonal therapies is effected by triggering of a programmed cell death pathway. Clinical progress has already been achieved through basic advances: receptor assays, for example, now permit prediction of treatment benefit in various settings.
INTRODUCTION
It is timely to reflect upon Beatson's century-old observation of metastatic breast cancer regression after oophorectomyI , Mixed feelings may be provoked by this exercise: pride, on the one hand, as to the contribution that this and other clinical observations have made to hormonal cancer therapeutics; but also concern about the pace of progress over the last 100 years. Indeed, a pessimist could argue that the only substantive practical advance over this period has been the substitution of oral drug therapy for ablative endocrine surgery. In this brief review we seek not only to define the obstacles to progress but also to redress the impression of therapeutic stagnation.
To consider this topic it is important first to define the spectrum of relationships between hormones and cancer ( Table 1) , Hormones are peripatetic signalling molecules which come in a variety of structures, including steroid hormones (e.g. androgens, oestrogens, progesterone, cortisone, aldosterone), sterols (e.g. retinoids, vitamin D), iodotyrosine-derived hormones (thyroxine and triiodothyronine), and peptide hormones. Cancers may cause 'hormonal symptoms' either via direct hormone release or via indirect effects on the normal endocrine system. In addition, they may invade endocrine organs-for example, the adrenals-though not usually with hormonal sequelae. Hormones can also playa key role in the pathogenesis and/ or progression of certain cancers; many, though not all, such cancer types are treatable by hormonal manipulation. It is this latter group of cancers which forms the focus of the following discussion. example, insulin-like growth factor-l (IGF-l) enjoys dual status as both a 'growth-factor' and a circulating proteinbound hormone; of note, its role as a 'second signal' in growth-hormone-dependent acromegaly makes it one of the few polypeptide growth factors firmly implicated in the phenotype of a human neoplastic disorder. Leaving aside questions of definition, it is the consequences of receptor activity which form the focus of most basic research. Table 2 summarizes some of the recognized effects of hormone receptor activation in mediating either tumour formation or phenotype, illustrating in turn the heterogeneity of such interactions. Notwithstanding this heterogeneity, all common hormonedependent cancers (those affecting the breast, prostate, endometrium and thyroid) regulate their hormone-responsive behaviour via nuclear receptors of the steroid hormone receptor superfamily. Receptor assays have not proven to be of routine clinical value in prostate cancer, however-partly because most of these tumours are initially hormoneresponsive.
Variations in the structure (and hence function) of molecules involved in hormone signalling pathways may be responsible for the pathogenesis or progression of some 'hormonal' tumours. Examples of neoplastic conditions arising from constitutively mitogenic mutations include those involving G protein-coupled receptors (e.g. activating Table 2 Hormone-receptor Interactions in cancer. Hormone receptor activation may mediate either the pathogenesis or the phenotype of the tumour in question mutations of the thyrotropin receptor, causing some functioning thyroid adenomas); G-proteins (e.g. GslX mutations-so-called asp oncogenes-causing acromegaly, but note that the overexpressed hormone responsible for the phenotype, growth hormone, itself activates a cytokine receptor); or cytokine receptors (e.g. activating mutations of the erythropoietin receptor causing familial erythrocytosis due to erythropoietin hypersensitivity, or of other granulocytic growth factor receptors leading to leukaemia/). Receptor tyrosine kinase mutations have been implicated in the pathogenesis of sporadic thyroid cancers as well as in the inherited syndrome of multiple endocrine neoplasia type n 3 ;
however, no unequivocal abnormality of growth factor expression has been defined in these or other neoplasms. Indeed, the popular models of 'paracrine' and 'autocrine' tumorigenesis remain wholly justified by correlative data.
The relevance of steroid hormone receptor mutations for the pathogenesis of disease is likewise unclear. Androgen receptor (AR) mutations have been reported in prostate cancer 4 .s, while oestrogen receptor (ER) mutations'', splice variants/ and gene methylation events'' occur in breast cancer. There remains considerable uncertainty, however, as to the frequency and phenotypic relevance of these structural variants". While the following discussion addresses hormone-dependence mediated via the steroid hormone receptor superfamily, it should be noted that newer drugs such as the somatostatin analogues also permit 'antihormonal' (as distinct from antineoplastic) management of syndromes involving overactivity of peptide hormone signalling pathways", The second major paradigm shift to have occurred in this field relates to the clinical effects of hormonal manipulation. Earlier models of anticancer drug action distinguished between 'cytotoxic' and 'cytostatic' mechanisms, with putative non-cytotoxic drugs such as tamoxifen regarded as blocking growth but not actively killing cells. Since it was well recognized that such hormonal manipulations often resulted in massive tumour regression, this view remained discordant with clinical observation. Such anomalies have been potentially resolved in recent years with the advent of a new model for drug-induced cell death-namely, programmed cell death or apoptosis10. Prior to this concept, cell death had been assumed to result from the accumulation of genetic damage or errors; hence, the induction of such damage by DNA-interactive cytotoxic drugs was readily explained. More recently it has been demonstrated that a specific intracellular 'death pathway' can be triggered by a variety of stimuli-including the withdrawal of hormone-dependent cell 'survival factors'.
Hormones
Hence, the biochemical pathways mediating death of cancer cells treated with cytotoxic drugs and hormones may be similar, albeit less directly activated by hormonal therapies. While the apoptosis paradigm represents an attractive explanation for the efficacy of hormonal tumour lysis, evidence for this remains circumstantial and in some test systems data have been conflicting!", None the less, apoptosis provides the only coherent model for the action of hormonal anticancer treatments at present, and sufficient positive data have been reported to support the credibility of this model!".
Improved understanding of this process may help explain still-mysterious clinical phenomena such as the therapeutic efficacy of receptor agonists-for example, oestrogens in breast cancer-which might otherwise be expected to directly promote tumour growth. The fuzzy divide between hormone agonists and antagonists in this field has not yet been clarified by this line of reasoning: witness the uncertain relationship between tumour flare and response (see below), and the unexpected induction of 'oestrogen-inducible' endometrial cancers by the 'anti-oestrogenic' drug tamoxifen (which, notwithstanding its status as a partial agonist, could quite credibly have exerted a protective effect). A potential explanation is that ER acts as a tumour suppressorl i-!" rather than a dominant oncogene, but this hypothesis in tum raises questions as to the precise pathogenetic significance of tumour ER overexpression. These persisting uncertainties have perhaps their most disturbing ramifications in the continuing debate over the risks of oestrogen replacement therapy in precipitating new breast cancers or reactivating previous disease15.
CLINICAL OBSERVATION AND THERAPEUTIC PROGRESS
The final arbiter of validity for any biomedical hypothesis is its success or failure in clinical application, but the latter outcomes are not always easy to judge. For example, the thyroid stimulating hormone (TSH)-dependence of (differentiated) thyroid cancer growth was first suggested by anecdotal reports of rapid metastatic tumour growth following thyroidectomy, and later supported by similar observations when thyroxine was withdrawn as a preliminary to radioiodine administration. Yet although the rationale for postoperative TSH suppression is convincing 1 6, few systematic studies have confirmed the survival value of this treatment over and above that attributable to radioiodine therapy. Thyroxine is none the less routinely prescribed, especially in the setting of paediatric radiation-induced tumours where recurrence rates appear reduced. In contrast, TSH suppression is no longer appropriate as the sole means of characterizing benign nodular disease17, given the unacceptable sensitivity and specificity of this manoeuvre and the ready availability of fine needle aspiration cytology.
Another poorly-documented hormonal phenomenon is that of tumour flare-a transient iatrogenic worsening of metastatic symptoms, particularly in bone, typically associated with pain and hypercalcaemia. The most serious complications of flare tend to occur in patients with prostate cancer who have osteoblastic disease in the vertebral column. Manoeuvres such as abrupt discontinuation of androgen inhibition, commencement of luteinizing hormone-releasing hormone (LHRH) agonists prior to antiandrogens, or experimental androgen 'priming' can result in spinal cord compression. None the less, flare occurs more commonly in breast cancer-with the weak oestrogen agonist tamoxifen being the usual cause, if only by virtue of its popularity. While it is widely assumed that oestrogens are more potent inducers of flare than antioestrogens, little documentary evidence for this conclusion is available. Treatment can generally be recommended after resolution of acute flare symptoms. Interestingly, however, the occurrence of flare does not correlate well with therapeutic outcome, and most series have suggested no firm trend with respect to either subsequent hormone-resistance or hormone-responsiveness. 'Withdrawal responses' are similarly anecdotal, being well described following cessation of either tamoxifen (in breast cancer) or flutamide (in prostate cancer); confusingly, flutamide withdrawal is not uncommonly associated with flare.
Therapeutic progress often seems a marginal concept in oncology and hence may require large andlor repeated clinical trials for its validation. An illustrative example concerns the development of effective adjuvant systemic (including hormonal) therapy for primary breast cancer. Studies over the last decade have indicated that appropriate adjuvant drug treatment may reduce the disease-specific odds of death by as much as 35% in some patient subgroups, though as few as 4%-8% of unselected patients enjoy an 'absolute' (overall survival) benefit. Adjuvant medical therapy therefore represents the only proven way of prolonging survival in breast cancer, though the extent to which this benefit reflects a 'cured' cohort versus a prolongation of time to relapse (affecting a larger cohort) remains uncertain. Since receptor assays appear to predict this benefit 18 ,19, this investigation is likely to become mandatory in this therapeutic context. Hence, adjuvant hormonal treatment is routinely used in both breast and differentiated thyroid cancer, though only of proven value in breast cancer. Curiously, such treatment has not yet been shown to be useful in either prostate or endometrial cancer ( Table 3) .
As in the adjuvant treatment of breast cancer, tumour receptor status is also predictive of benefit in the setting of metastatic breast and endometrial cancer ( Table 4 ). Disease response can be readily monitored with tumour markers in Table 3 Adjuvant endocrine treatment. Although used experimentally In prostate and endometrial cancer, adjuvant treatment is only routinely undertaken in breast and thyroid cancer, and only of proven value in the former many hormone-dependent malignancies: measurement of prostate-specific antigen (PSA) in metastatic prostate cancer, and of thyroglobulin in metastatic thyroid cancer, is especially helpful. Such markers provide a far cheaper and more sensitive disease monitor than do radiographic studies of bone disease, for example. Markers of this type cannot be used to monitor the appropriateness of adjuvant treatment, of course, so the choice of adjuvant treatment is something of a lottery. A radical solution is to treat selected adjuvant patients 'upfront' with hormonal (or cytotoxic) therapy prior to tumour rernoval/", and to use the disappearance of the primary tumour as an index of therapeutic appropriateness. Neoadjuvant hormonal administration is being similarly used to 'downstage' prostatic primaries before radical prostatectomy, though the survival benefit of this approach is not yet proven/I. Much effort has gone into characterizing the endocrine changes occurring in patients undergoing hormonal anticancer treatment and relating these to clinical response. In breast and prostate cancer, for example, many drug therapies have been analysed in terms of the degree of sex hormone (oestrogen or androgen) suppression achieved. Perhaps surprisingly, the correlations reported between the latter measures and tumour response have not been strong. A related observation is that the proportion of patients responding to different hormonal manipulations in the same clinical context (e.g. first-line treatment of metastatic breast cancer) tends to be remarkably similar-averaging around 30% in the latter example, irrespective of whether treatment is with tamoxifen, oestrogens, progestins, androgens, LHRH agonists, oophorectomy or hypophysect-omy22.
PATHWAYS VERSUS PILLS
These findings suggest that the choice of hormonal manipulation is not the critical variable in determining response. Rather, it is the characteristics of the target biochemistry which predict response-the best predictor of this pathway currently being receptor overexpression, at least in breast cancer (ER and progesterone receptor, PR) and endometrial cancer (PR). The second conclusion from these observations is that a response of this pathway (such as may trigger apoptosis, for example) appears to depend less on the potency of the drug than on whether a 'threshold' change in biochemical function is induced. The failure of maximal androgenic blockade to provide substantially superior prostate cancer outcomes to monotherapy/J supports this view, though the continuing popularity of such approaches bears witness both to their theoretical appeal and to the efficacy of promotional efforts by pharmaceutical companies. Certainly, there has been no evidence for additive benefit of hormonal combinations in breast cancer/", a disease in which clinical experience is far wider. Clinical observations thus suggest that hormonal responsiveness may have the characteristics of an 'allor-nothing' phenomenon. While by no means proven, this view raises the possibility that a therapeutic quantum leap in this field is unlikely to result from modifications of existing treatment approaches-such as the formulation of 'pure' antioestrogens or the induction of 'complete' hormonal blockade with combination treatments. More likely, the critical advances will relate to mechanisms underlying progression to hormone-independence.
Successful palliation of advanced disease with hormone treatment is one of the more gratifying therapeutic experiences in the management of common cancers. The flip side of this experience occurs when previously hormoneresponsive disease becomes frustratingly resistant to both ongoing treatment and to further manipulations-this being an especially limiting problem after first-line palliation of metastatic prostate cancer. Whether or not the latter complication is 'hard-wired' (e.g. the result of a mutational event affecting the hormone receptor, or some other Ca endometrium 452 overriding oncogenic molecule) is a central issue for clinicians and researchers alike. However, there are few data to support the notion that a critical molecular change is responsible for this phase of tumour evolution.
DISEASE PROGRESSION TO HORMONE-INDEPENDENCE
An alternative possibility is that the tumour phenotype gradually 'adapts' to the hormonal manipulation in such a way as to restore growth. One mechanism which has been suggested involves receptor down-regulation in response to (say) the continued presence of a partial agonist. According to this model, chronic treatment with tamoxifen could eventually lead to homoeostatic downregulation of ER, leading secondarily to acquired drug resistance. A strategy currently being explored with this possibility in mind (particularly in prostate cancer) is that of intermittent hormone treatment-i-c-in other words, patients are regularly given a 'breather' from active therapy instead of continuing on treatment until progression 26 . While the results of this approach are not yet clear, similar efforts have been made to restore progesterone receptor expression in endometrial cancer by co-administration of tamoxifen as the upregulating principle/". No positive benefits have been linked to this intervention, however 28 ,29. Conceivably, the promising second-line benefit of drugs such as dexamethasone in prostate cancer could reflect the targeting of a receptor pathway distinct (at least initially) from that targeted by first-line medication.
Hormone resistance could also be acquired via the clonal outgrowth of tumour cell subpopulations expressing other oncogenic signalling pathways. For example, a reciprocal relationship has been noted in some tumour types between steroid hormone receptor overexpression and 'growth factor receptor' (e.g. epidermal growth factor receptor, c-erbB-2) overexpression 3 0-32-raising the possibility that these different phenotypes may reflect distinct tumorigenetic pathways. Such associations raise testable hypotheses about the mechanisms underlying tumour progression to hormone-independence, and suggest pharmacological otrategies for circumventing this key clinical problem.
THE FUTURE OF ENDOCRINE INTERVENTION IN ONCOLOGY
When we look at the broad sweep of twentieth-century cancer treatment, a strong candidate for the most successful anticancer drug is tamoxifen. Based on a physiological interaction with an endogenous regulatory molecule, it is both well-tolerated and effective in a high proportion of patients. What rational strategies do we have, then, for developing a 'second tamoxifen'-a drug which potently targets yet another tumour-specific biochemical pathway? Not until we have solved this conundrum-in terms of basic biology, certainly, but also in terms of hands-on drug development-will we be able to look forward confidently to a twenty-first-century revolution in hormonal anticancer therapeutics.
